Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new data on ...

Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.

Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that the Committee ...

Agios maintains a robust balance sheet and is positioned for significant growth if regulatory approvals and market expansion ...

Dr. Mary Erika Orteza, Medical Officer IV, Baguio General Hospital and Medical Center. BAGUIO CITY (PIA) — In line with the observance of Newborn Screening (NBS) Month this October and Newborn ...

Agios Pharmaceuticals (AGIO) announced that new data on mitapivat, an oral pyruvate kinase activator, will be featured in oral and poster ...

Discover key Q3 2025 insights from Agios Pharmaceuticals' earnings call—PYRUKYND progress, revenue growth, global launches, and regulatory updates.

Research and Development (R&D) Expenses were $86.8 million for the third quarter of 2025, an increase of $14.3 million compared to the third quarter of 2024. The year-over-year increase was primarily ...

PYRUKYND® (mitapivat) net revenuesPDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025CHMP adopted positive opinion for PYRUKYND in thalassemia ...

Expanded Dose Exploration in Part A and Dose Escalation in Part B of BEAM-302 Phase 1/2 Study in Alpha-1 Antitrypsin ...